Aurinia Pharmaceuticals Gets 91% Upside PT From Canaccord Genuity

Aurinia Pharmaceuticals got a new $11 price target from Canaccord Genuity today. Dang! That's only 91.3% upside from the current price of $5.75!

The upgrade seems to be about Voclosporin (VCS), Aurinia Pharmaceutical's investigational therapy for patients with active lupus nephritis and moving through Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by Big Pharma companies looking for the next multi-billion dollar drug (FBR projects VCS could achieve more than $2 billion in annual peak sales), Aurinia could receive an acquisition bid from a Big Pharma company at $11 per share.

Inphi Corporation Has Honey Badger Large Players

Inphi Corporation has an incredible strong uptrending large players volume. What's really amazing about it is that the stock has had big volatile swings but the large players volume just keeps on steadily rising.

On October 18, 2017, Jefferies Group set a price target of $50 which is 33.33% upside from its current price.

T-Mobile US Inc Stock Has Massive Rise In Large Players Volume

T-Mobile US Inc. stock has formed a massive positive divergence on large players volume. Analysts with Societe Generale gave a Buy rating on T-Mobile stock and set a $71 price target (15.5% upside from the previous close of $61.47).

T-Mobile currently has 1 Sell rating, 8 Hold ratings, 17 Buy ratings, and 1 Strong Buy rating. The consensus price target is $70.03 which represents 13.93% upside from the current price.

Acacia Communications Gets Buy Rating From Needham & Company

Acacia Communications had its Buy rating reaffirmed by Needham & Company. Needham raised their price target to $50. Needham & Company has one of the best track records in the industry.

MKM Partners also has a Buy rating on Acacia Communications stock, with a price target of $61.

Sofi AI Market Sentiment Gauge

Sofi AI Market Sentiment Gauge

Market is extremely oversold. Good time to take long positions.